tbuckley/cabot-search huggingface dataset:
Association of Mosaic Loss of Chromosome Y with Lung Cancer Risk and Prognosis in a Chinese Population
Authors: Na Qin, Ni Li, Cheng Wang, Zhening Pu, Zijian Ma, Guangfu Jin, Meng Zhu, Min Dai, Zhibin Hu, Hongxia Ma, Hongbing Shen
Journal: Journal of Thoracic Oncology (2018)
Gene expression profiles in A549-NFkB reporter cells following exposure to smoke condensate from cigarettes that burn or primarily heat tobacco
Authors: Wanda Fields, Mary Borgerding, Betsy Bombick, David Doolittle
Journal: Cancer Research (2007)

4275  Alterations in signaling pathways associated with oxidative stress, inflammation and DNA damage are often observed in cells exposed to complex chemical mixtures including cigarette smoke. Our laboratory previously reported that smoke condensate from cigarettes that primarily heat tobacco produce less change in p21, GADD45, COX-2, IL-8, HO-1 and HSP70 mRNA levels in normal human bronchial epithelial (NHBE) cells than smoke condensate from tobacco-burning cigarettes. The NFκB signal transduction pathway is reported to mediate in part the response of bronchial epithelial cells to cigarette smoke through the activation of several genes; including genes coding for COX-2, HO-1, and HSP-70. The objective of this study was to characterize and compare the effect of smoke condensates from tobacco-heating and tobacco-burning cigarettes on NF-κB promoter activation. Cigarette smoke condensate (CSC) was prepared from Kentucky reference 2R4F cigarettes, a tobacco-burning product designed to represent the average low “tar” cigarette in the US market and Eclipse, a cigarette that primarily heats tobacco. A549-NFκB reporter cells stably transfected with a NFκB-luciferase plasmid were exposed to each CSC and NFκB activation was determined by measuring changes in luciferase activity in cell lysates via a standard luciferase assay. Changes in mRNA levels were determined by quantitative RT/PCR. Luciferase analysis of NFκB promoter activation revealed dose- and time-dependent activation following exposure to either condensate. HO-1 and COX-2 mRNA levels were temporally regulated and significantly increased (p
A Not-So-Simple Groin Mass
Authors: Priti Lalchandani, Ashkan Moazzez
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Integrating patient-reported outcomes data into the electronic health record.
Authors: Brandon Bosch, Scott Hartman, Lauren Caldarello, Diane Denny, DBA
Journal: Journal of Clinical Oncology (2018)

186 Background: As a national network of hospitals that specialize in the treatment of patients fighting complex or advanced-stage cancer, the network was an early adopter of using patient reported outcome (PRO) data as part of its routine patient assessment and treatment. Since 2012 an externally validated tool has been used to capture patients’ perceived symptom burden for real-time clinical intervention, from the point of first visit throughout the course of treatment, at intervals of 21 days or greater. Research has demonstrated the use of PRO data as a valuable component of a patient’s treatment plan, promoting improved quality and length of life. Methods: The use of this data across the network was expanded such that results once only accessible on paper and via electronically stored images, has now been fully integrated into the electronic health record (EHR). A multidisciplinary project team formulated the specifications for a successful integration of PRO data into the EHR. Results: The project achieved its goal and went beyond data integration to include implementation of a solution to facilitate documentation of intervention against patients’ symptoms. Provider workflow efficiency is greatly enhanced via single system access and visual notification, with critical values flagged, to focus providers’ attention on severe symptoms. Incorporation of a unified EHR flowsheet provides a paperless, one-stop symptom assessment approach and streamlined mechanism for intervention documentation. The documentation module leverages structured data fields and linkage of PRO data with interventions, such as specialist referrals or medication orders, to support enhanced patient care and quality improvement. Conclusions: The ability to easily view an array of patient reported concerns and document interventions against severe or significantly worsening symptoms provides clinicians an enhanced ability to address quality of life related needs. PRO data is now stored electronically in the enterprise warehouse, thus enabling aggregation with data from which to perform population analysis and eventually, pursue opportunities for predictive modeling.
Quantitative profiling of cytokines and chemokines in <scp>DOCK</scp>8‐deficient and atopic dermatitis patients
Authors: Minnie Jacob, Duaa Bin Khalaf, Safa Alhissi, Rand Arnout, Bander Alsaud, Hamoud Al‐Mousa, Andreas L. Lopata, Anas M. Alazami, Majed Dasouki, Anas M. Abdel Rahman
Journal: Allergy (2018)

Abstract Background Hyper‐IgE syndromes ( HIES ) are a clinically overlapping, heterogeneous group of inborn errors of immunity characterized by elevated serum IgE level, eosinophilia, atopy, and immune dysregulation. Deficiency of DOCK 8 protein is potentially a life‐threatening autosomal recessive HIES and only curable with bone marrow transplantation. Hence, the diagnosis of DOCK 8 deficiency is critical and should be sought at an early stage to initiate definitive therapy. Methods Serum samples from patients with DOCK 8 deficiency and atopic dermatitis were profiled on a cytokine/chemokine panel for potential differential expression. Results CXCL 10 and TNF ‐A were upregulated in DOCK 8 patients when compared to AD , possibly contributing toward increased susceptibility to infections and cancer. In contrast, epidermal growth factor ( EGF ) was significantly downregulated in a subgroup of DOCK 8‐deficient and AD patients, while IL ‐31 expression was comparable between both DOCK 8‐deficient and AD cohorts, possibly contributing toward pruritus seen in both groups. Conclusion This comprehensive cytokine profile in HIES patients reveals distinctive biomarkers that differentiate between the DOCK 8‐deficient and AD patients. The unique expression profile of various inflammatory cytokines in patients with DOCK 8 deficiency vs atopic dermatitis likely reflects disease‐specific perturbations in multiple cellular processes and pathways leading to a predisposition to infections and allergies seen in these patients. These data agree with the role for EGF replacement therapy in EGF ‐deficient individuals with AD as well as DOCK 8 deficiency through a potential shared pathway. In addition, these novel biomarkers may be potentially useful in distinguishing DOCK 8 deficiency from AD allowing early‐targeted treatment options.
Standardization of inpatient CPR status discussions and documentation within the division of hematology-oncology at UPMC Shadyside: Results from PDSA cycle 1 and 2.
Authors: Christine Ann Garcia, Mamta Bhatnagar, Rachel Rodenbach, Edward Chu, Stanley M. Marks, Abigail Graham-Pardus, Jamie Kriner, Melissa Winfield, Christopher Minnier, Janet Leahy, Sharon Hanchett, Emily Baird, Joshua Levenson
Journal: Journal of Clinical Oncology (2018)

257 Background: In December 2016, 49% of patients admitted to inpatient oncology services at UPMC Shadyside had CPR status discussion documentation prior to discharge. This project aims to improve quality and rates of CPR status conversations. Methods: During Plan-Do-Study-Act (PDSA) cycle 1, a stakeholder workgroup was formed in January 2017 by oncology faculty, fellows, nurses and advance practice providers (APPs), medicine house staff, and palliative care faculty. All oncology clinicians were reminded weekly to discuss and document CPR status preferences. APPs received communication training with palliative care specialists. Oncology leadership received a monthly update of CPR status documentation rates, and endorsed CPR status best practice guidelines developed by the workgroup. For PDSA cycle 2, patient charts without CPR status documentation in March 2018 were reviewed. Results: PDSA cycle 1 resulted in CPR status assessment rates increasing from 49% to &gt; 80%. 1400+ more CPR status discussions were documented in 2017 than 2016. The percentage of patients discharged “Comfort Measures Only” or “Do Not Resuscitate” increased from 14.2 (S.D. 2.4) to 20.0 (S.D. 2.1). For PDSA cycle 2, 60 patients without CPR assessment were reviewed. Fifty-two percent were admitted overnight by nocturnists, 48% by daytime APPs, and none by housestaff. 55% (33/60) had metastatic disease. Fifty-three percent (31/60) of patients had prior CPR status documentation in the past 12 months. Fifteen percent (11/60) of patients were admitted for scheduled inpatient chemotherapy. Conclusions: PDSA 1 showed that standardization of CPR status assessment with formal training increased CPR status assessments. More patients wanted CMO or DNR when asked, which may indicate the need for earlier goals of care discussions. PDSA 2 indicated that focusing efforts on completing CPR assessment as part of the admission process, especially for scheduled inpatient chemotherapy admissions, is critical in further improving our rates.
Responding to the opioid crisis in a manner that respects oncology patients: A single institution experience writing policy to promote safe opioid use.
Authors: Cristina Cellurale, Mary Anne Fenton, Katie Cherenzia, Megan Begnoche
Journal: Journal of Clinical Oncology (2018)

132 Background: The current opioid crisis has had wide ranging implications across medicine and in particular oncology practice. Opioids have been used for centuries for their analgesic properties. As physicians and historians are aware, the abuse potential of opioids is significant. Despite this, a dramatic shift in medical education in the late 1990s and early 2000s and aggressive marketing and manufacture of opioids has led to widespread opioid misuse and abuse. Therefore, a slew of regulations has been put into effect within a brief period of time. Among practitioners, the oncologist holds a unique and arguably more challenging role, caring not only for those with acute cancer-related pain or those at the end of life, but also for cancer survivors or those who live with their cancer as a chronic condition. ASCO has put forth comprehensive guidelines for the safe use and monitoring of opioids. The ASCO policy statement also highlights the significant barriers that oncology patients face, thereby maintaining a focus on the unique needs of this patient population. Methods: The Lifespan Cancer Institute is an academic practice and writes approximately 880 opioid prescriptions each month with approximately 15% being new prescriptions. Our Multidisciplinary Quality Team implemented a safe opioid prescribing initiative including patient education sheets, an electronic patient-provider treatment agreement, and an electronic template for provider documentation. Our palliative care team monitors pain scores. Results: During month one, 16% of patients newly prescribed an opioid had a completed patient-provider treatment agreement. For the second month, the number of completed agreements increased to 29%. Conclusions: Given the prevalence of opioid misuse, there is a growing overlap between oncology patients and those with opioid misuse disorder. Given high levels of psychological distress, the cancer patient is at risk for opioid misuse. Furthermore, oncology patients can be victims of diversion. Our responsibility is to screen and educate patients on the risk of opioid addiction and diversion while providing compassionate palliative care.
Abstract 19938: VEriciguat NItroglycerin Clinical IntEraction (VENICE): A Phase 1, Multicenter, Randomized, Placebo-controlled, Double-blind Group-comparison Study in Patients With Stable Coronary Artery Disease to Evaluate Tolerability and Blood Pressure Effects of Nitroglycerin After Pre-treatment With Multiple Oral Doses of Vericiguat
Authors: Hans-Dirk Duengen, Frank Donath, Gerd Mikus, Nikos Werner, Petra A Thuermann, Mahir Karakas, Boris Weimann, Tanja Koch, Michael-Friedrich Boettcher, Corina Becker
Journal: Circulation (2017)

Introduction: Vericiguat is under investigation in the phase 3 VICTORIA study (NCT02861534) in patients with HFrEF. Guidelines recommend nitroglycerin (NTG) for acute angina in patients with CAD, a...
Hemorrhagic Highs from Synthetic Cannabinoids — A New Epidemic
Authors: Jean M. Connors
Journal: New England Journal of Medicine (2018)

Reports of clusters of persons with severe side effects from synthetic cannabinoid use are not new and often occur when new synthetic cannabinoids with different side-effect profiles are introduced1 or when other psychoactive drugs are added to a synthetic cannabinoid. In this issue of the Journal, Kelkar et al. describe the treatment of patients who presented with coagulopathy and bleeding after using synthetic cannabinoids.2 An alarming finding in their report was that the synthetic cannabinoids were mixed with brodifacoum, a bromophenyl derivative of warfarin, which resulted in severe and long-lasting coagulopathy in users. As of July 13, 2018, a total . . .
Abstract 19444: Physical Activity and Heart Failure Incidence Among Postmenopausal Women in the Women’s Health Initiative Study
Authors: Michael J LaMonte, Joseph C Larson, JoAnn E Manson, Andrea K Chomistek, Wenjun Li, Jennifer W Bea, Cora E Lewis, Karen C Johnson, Jean Wactawski-Wende, Charles B Eaton
Journal: Circulation (2016)

Background: Heart failure (HF) imposes a growing burden to public health, disproportionately affecting adults 65 years and older. Physical activity (PA) has been associated with lower HF risk in mi...
Annual colorectal cancer screening in rural community clinics using the fecal immunochemical test (FIT): Second and third year screening.
Authors: Connie Arnold, Terry C Davis, James Morris, Glenn Morris Mills
Journal: Journal of Clinical Oncology (2018)

35 Background: Colorectal cancer (CRC), the second leading cause of cancer death in the US, can be significantly reduced if it is detected early. Although overall CRC screening rates have increased significantly, disparities persist among low income individuals, adults with low literacy and those living in rural areas. Methods: Randomized controlled trial to assess the effectiveness of 2 health literacy informed phone follow-up strategies to improve annual screening with Fecal Immunochemical Test (FIT) in 4 rural community clinics. Eligible patients, age 50-75, were recruited. After consenting, a research assistant (RA) recommended screening and gave literacy and culturally appropriate education using a pamphlet, the FIT kit, simplified instructions and a demonstration of how to use it, At 4 weeks patients who had not returned their kit receive either 1) a personal follow-up call (PC) from a central RA using motivational interviewing skills and reminding them to complete FIT kits; or 2) an automated follow-up call (AC) using plain language and motivational messages encourages patients to complete the FIT. During years 2 and 3, FIT kits were mailed to patients. Follow-up call procedures previously used were followed. Results: 620 patients not up-to-date were enrolled: 308/AC &amp; 306/PC; 66% were African American, 55% women; 40% had limited literacy. During Year 1, 69% completed screening in AC arm versus 67% in PC arm. During Year 2, percentage screened decreased: 40% screened in AC arm and 37% in PC arm. Number of patients that needed at least one follow-up called increased: 74% in both arms needed at least 1 reminder call. Among those called, 19% in the AC arm completed their kit versus 15% in the PC arm. To date in Year 3, 32% screened in AC and 34% in PC. Conclusions: Simplified instructions accompanied by a face-to-face demonstration of FIT, use of “teach back” to confirm understanding with a follow-up call if needed, facilitated completion rates of all patients, particularly those with limited literacy. The less costly and time consuming automated call was equally effective as a personal call. Screening rates in years 2 and 3 declined. CRC screening with FIT is only effective when completed annually. Clinical trial information: RSG-13-021-01 - CPPB.
miR-3687 Overexpression Promotes Bladder Cancer Cell Growth by Inhibiting the Negative Effect of FOXP1 on Cyclin E2 Transcription
Authors: Qipeng Xie, Caiyi Chen, Haiying Li, Jiheng Xu, Lei Wu, Yuan Yu, Shuwei Ren, Hongyan Li, Xiaohui Hua, Huiying Yan, Dapang Rao, Huxiang Zhang, Honglei Jin, Haishan Huang, Chuanshu Huang
Journal: Molecular Therapy (2019)

Cyclin E2, a member of the cyclin family, is a key cell cycle-related protein. This protein plays essential roles in cancer progression, and, as such, an inhibitor of cyclin E2 has been approved to treat several types of cancers. Even so, mechanisms underlying how to regulate cyclin E2 expression in cancer remain largely unknown. In the current study, miR-3687 was upregulated in clinical bladder cancer (BC) tumor tissues, The Cancer Genome Atlas (TCGA) database, and human BC cell lines. Inhibition of miR-3687 expression significantly reduced human BC cell proliferation in vitro and tumor growth in vivo, which coincided with the induction of G0/G1 cell cycle arrest and downregulation of cyclin E2 protein expression. Interestingly, overexpression of cyclin E2 reversed the inhibition of BC proliferation induced by miR-3687. Mechanistic studies suggested that miR-3687 binds to the 3' UTR of foxp1 mRNA, downregulates FOXP1 protein expression, and in turn promotes the transcription of cyclin E2, thereby promoting the growth of BC cells. Collectively, the current study not only establishes a novel regulatory axis of miR-3687/FOXP1 regarding regulation of cyclin E2 expression in BC cells, but also provides strong suggestive evidence that miR-3687 and FOXP1 may be promising targets in therapeutic strategies for human BC.
Secondary and Tertiary Transmission of Vaccinia Virus After Sexual Contact with a Smallpox Vaccinee — San Diego, California, 2012
Authors: Hai Shao, Eric C. McDonald, Michele M. Ginsberg, Lisa M. Yee, Jay R. Montgomery, Frances Allan-Martinez, Mary G. Reynolds, Danielle M. Tack, Whitni Davidson, Nishi Patel, Rachael Joseph
Journal: MMWR Morbidity and Mortality Weekly Report (2013)
Abstract 19461: Longitudinal Examination of Neuropsychological and Functional Cognition Outcomes in Patients Following Therapeutic Hypothermia After Cardiac Arrest
Authors: Kelly Wilson, Kyle Harvison, Mary Radomski, Ross Garberich, Sue Sendelbach
Journal: Circulation (2016)

Introduction: Therapeutic hypothermia after cardiac arrest has been shown to increase survival to discharge and neurologic recovery. However, neurologic recovery is usually measured by Cerebral Performance Category (CPC) scores that do not discriminate well at the high end of neurological function. Thus, there are significant gaps in knowledge, underlying an important aspect of care related to the assessment and management of education of patients and families about what to expect during the vulnerable transition period from discharge to home and recovery once at home (e.g., return to work, driving). Methods: This longitudinal, descriptive cohort study examined neurological (cognitive function, language, attention) and functional cognition before hospital discharge and at the 3-6 weeks post-discharge follow up clinic appointment in patients undergoing therapeutic hypothermia after cardiac arrest. Results: Of the 13 patients who participated, mean age was 59 years with 77% being male; 77% married or in a m...
Abstract 10073: Characteristics of Very Late Stent Thrombosis Assessed by Coronary Angioscopy and Histopathology of Aspirated Thrombus
Authors: Kosuke Fujita, Masafumi Ueno, Shinichiro Ikuta, Takayuki Kawamura, Masakazu Yasuda, Tomoyuki Ikeda, Takashi Nakamura, Kazushi Saratani, Yoshitaka Iwanaga, Shunichi Miyazaki
Journal: Circulation (2015)

Background: The mechanisms of very late stent thrombosis (VLST) have not been fully elucidated and may involve multiple factors. The aim of this study was to evaluate characteristics of VLST based on angioscopy and histopathology of aspirated thrombus. Methods: Coronary angioscopy was performed in all stent thrombosis cases to evaluate the culprit lesion. The mechanisms of VLST were divided according to two factors by angioscopic findings such as uncovered struts and neoatherosclerosis. Uncovered struts were defined as stent struts uncovered by neointima. Neoatherosclerosis was defined as stent struts covered by yellow neointima. Furthermore, aspirated material was collected for assessment of atherothrombotic characteristics in all cases. Results: From February 2011 to April 2015, emergency PCI for acute myocardial infarction was performed in 336 patients, with 13 of these cases due to stent thrombosis. Clinical characteristics of VLST patients are shown in Figure. In uncovered struts, all 3 cases were not on any antiplatelet therapy prior to VLST, whereas patients with neoatherosclerosis were taking at least one antiplatelet agents except for one case. In the presence of neoatherosclerosis, thrombus with atheroma material was aspirated in 5 of 10 cases despite there was no atheroma material in patients with uncovered strut. The time period of occurrence of VLST was significantly shorter in patients with uncovered strut compared with neoatherosclerosis (48.6±12.5 month vs. 84.3±6.9 month, p=0.03) In 13 case of VLST, peri stent contrast staining (PSS) was found in 1 case of each neoatherosclerosis and uncovered strut at the time of follow-up angiography. Conclusions: Discontinuation of dual anti platelet therapy was an important predictor for VLST, especially in patients with uncovered struts. However, most VLST weredue to neoatherosclerotic plaque rupture assessed by coronary angioscopy, which were also confirmed by histopathology of aspirated thrombus.
Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death
Authors: Kenneth H. Shain, Mark B Meads, Bin Fang, Linda Mathews, Jennifer Gemmer, Liang Nong, Ismael Rosado-Lopez, Jennifer E. Ring, Robert MacLeod, Lori Hazlehurst, Conor Lynch, Jonathan A. Pachter, William Matsui, John Koomen, Tuan Nguyen
Journal: Blood (2014)